Current Research in Translational Medicine
Scope & Guideline
Bridging Laboratory Discoveries with Clinical Excellence
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal consistently publishes research related to hematological cancers, including acute myeloid leukemia, lymphoma, and multiple myeloma, focusing on novel treatments and therapeutic strategies. - Translational Research:
A core aim is to translate laboratory findings into clinical applications, emphasizing studies that bridge experimental and clinical medicine. - Cell and Gene Therapy:
Research on cell-based therapies, particularly CAR-T cell therapy and stem cell transplantation, is a significant focus, highlighting advancements in treatment methodologies. - Immunotherapy:
The journal covers emerging immunotherapeutic strategies, investigating their efficacy and safety in treating various malignancies. - Biomarkers and Diagnostics:
There is a strong emphasis on identifying biomarkers for disease prognosis and treatment response, contributing to personalized medicine. - Regenerative Medicine:
Research involving stem cells and regenerative therapies is prevalent, showcasing innovative approaches to repair and regenerate damaged tissues. - Clinical Guidelines and Best Practices:
The journal also addresses clinical practices through guidelines and recommendations for managing hematological disorders.
Trending and Emerging
- CAR-T Cell and Novel Immunotherapies:
The increasing focus on CAR-T cell therapy and other immunotherapeutic approaches highlights the journal's commitment to cutting-edge treatments and their applications in hematological malignancies. - Next-Generation Sequencing and Genomics:
There is a growing trend towards incorporating genomic technologies such as next-generation sequencing, which aids in understanding the genetic underpinnings of diseases and personalizing treatment. - Biomarker Discovery and Application:
Research aimed at discovering and validating biomarkers for various hematological conditions is on the rise, enhancing the capabilities of precision medicine. - Artificial Intelligence and Data Analytics:
The integration of AI and data analytics in predicting treatment outcomes and patient responses is emerging as a significant trend, reflecting the journal's adaptation to technological advancements. - Regenerative and Stem Cell Therapies:
An increasing number of studies are exploring the potential of regenerative medicine and stem cell therapies, indicating a shift towards innovative approaches in treatment. - Clinical Guidelines and Evidence-Based Practices:
There is a noticeable trend towards publishing clinical guidelines and recommendations, aiming to standardize practices and improve patient care in hematological oncology.
Declining or Waning
- Solid Tumor Research:
Research specifically focused on solid tumors has decreased, indicating a shift towards hematological malignancies and therapies related to blood cancers. - Traditional Pharmacotherapy:
There appears to be a reduction in studies centered on conventional pharmacological treatments, as innovative therapies like immunotherapy and gene therapy become more prominent. - Infectious Disease Research:
While COVID-19 research was significant during the pandemic, the volume of papers addressing infectious diseases outside the context of hematological malignancies has lessened. - Basic Science Studies:
There is a noticeable decline in purely basic science research that does not directly translate to clinical applications, as the journal increasingly emphasizes translational studies.
Similar Journals
Hematology Transfusion and Cell Therapy
Connecting global experts in hematology and immunology.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
CURRENT OPINION IN HEMATOLOGY
Unveiling the latest trends in hematology for professionals.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
CANCER IMMUNOLOGY IMMUNOTHERAPY
Pioneering Research in Cancer ImmunotherapyCancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.
SEMINARS IN LIVER DISEASE
Pioneering discussions in the field of hepatology.SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.
Hematologie
Advancing the Science of Blood DisordersHematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.
Indian Journal of Hematology and Blood Transfusion
Illuminating the Path in Hematology and Transfusion PracticesIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Current Medical Science
Innovative Insights for Tomorrow's MedicineCurrent Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.
Experimental Hematology & Oncology
Driving Progress in Blood Health and Cancer SolutionsExperimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.
HEMATOLOGICAL ONCOLOGY
Transforming Knowledge into Practice in Hematological OncologyHEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.
CANCER AND METASTASIS REVIEWS
Fostering Innovation in Cancer Treatment StrategiesCancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.